E 1010

Drug Profile

E 1010

Alternative Names: ER 35786

Latest Information Update: 06 Aug 2007

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Antibacterials; Carbapenems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 06 Aug 2007 Discontinued - Phase-I for Bacterial infections in USA (IV)
  • 15 Feb 2002 An in vitro study has been added to the Bacterial Infections antimicrobial activity section
  • 26 Oct 2001 An in vitro study has been added to the Bacterial Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top